KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report

BACKGROUND: Close to one third of colorectal cancer (CRC) patients are diagnosed with metastatic CRC (mCRC). Patients with wild-type RAS and BRAF usually receive anti-EGFR monoclonal antibody therapy containing cetuximab. Overall, 30–50% of mCRC patients are reported to harbor RAS mutations, and RAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Qunli, Zeng, Zhu, Yang, Yang, Wang, Ya, Xu, Yongfeng, Zhou, Ying, Liu, Jinlu, Zhang, Zhiwei, Qiu, Meng, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207953/
https://www.ncbi.nlm.nih.gov/pubmed/35734602
http://dx.doi.org/10.3389/fonc.2022.872630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207953/
https://www.ncbi.nlm.nih.gov/pubmed/35734602
http://dx.doi.org/10.3389/fonc.2022.872630

Ejemplares similares